Performance of new methylation classifier vs old in #meningioma outcome classification #SNO2022

Costello Joe Costello / Okada Okada Lab @ UCSF labs with special guests UCSF Neurosurgery in #SNO2022!

Early-career setback and future career impact | Nature Communications nature.com/articles/s4146…

Thank you UCSF Helen Diller Family Comprehensive Cancer Ctr and Joe Costello for two amazing years. I was blessed to work with so many talented and lovely people! Next stop - Heidelberg!

What a great HertieNeuroscience symposium! Looking forward to the discussion on day 2 with all fellows from the participating sites! Charité - Universitätsmedizin Berlin Uniklinik Bonn UKE Hamburg Universitätsmedizin Mannheim @LMU_Uniklinikum Hertie-Zentrum für Neurologie Universitätsmedizin Mannheim Universitätsklinikum Heidelberg

Excited to finally visit Zürich again and speak at Neuro-Oncology_USZ Symposium about new molecular subtypes of IDH-mutant gliomas today! Looking forward to great discussions and a beautiful day in one of my favorite cities.

We have uncovered a new molecular mechanism responsible for nearly one-third of sporadic schwannomas – recurrent insertion/deletion mutations in 𝑆𝑂𝑋10. doi.org/10.1093/neuonc…

🧠 attention young and early career brain tumor investigators! ✨ Join us for the first-ever gathering of the #EORTC Brain Tumor Group Y-ECI. Don’t miss your chance to dive into the world of EORTC and connect with fellow Y-ECI over drinks 🍹

🧠🇪🇺🩺🔬👩‍⚕️💫 Join us at #EANO2023! Let’s tackle the challenges of growing towards independent clinician or scientist together. Stay tuned: sites.google.com/view/eano-eci #newPI #clinicianscientist OncoAlert EANO Thanks for full support Manuel Valiente Prof Susan Short

Today’s #EANO2023 Awardees Highlight✨brought to you from Germany! Areeba Patel from DKFZ was selected to receive the EANO Best Oral Presentation Award for Translational research & present her work about molecular diagnostics with Rapid-CNS2. Congratulations! OncoAlert IBTA

EANO ESTRO giuseppe Minniti Philipp Karschnia arjun sahgal Anca-L. Grosu, MD Excellent overview by Felix Sahm Sahm Lab on current standards in neuropathology

We're proud to present our latest work which is now out in Nature Communications : MYCN overexpression and loss of p53 is sufficient to drive malignant #glioma in mice corresponding to human diffuse paediatric-type high grade #glioma, MYCN subtype. nature.com/articles/s4146…

I am happy to announce that I will be funded by the Emmy Noether programme DFG public | @[email protected] . My group will focus on transcription factors in IDH-mutant giomas Universitätsklinikum Heidelberg

Apply now for the DKFZ #Postdoc|toral Fellowships at the German #Cancer Research Center, covering all areas of #cancerresearch, including #epigenetics, #genomics, #stemcells, #radiooncology, #epidemiology. To apply for your #PostdocFellowship visit ➡️ t1p.de/4t3fp

I'm deeply honored to receive the Sibylle-Assmus Award for Neurooncology 2024. I want to thank everyone who helped me along the way!

We are Hiring !! Please share and retweet ! The 3D-Brain Models Lab at the University Medical Center Freiburg is seeking talented individuals with a background in Neuroscience or Neurooncology to join our innovative research team. 🔗 Apply Now: glassdoor.de/job-listing/re…

📢 Just published in JCO! What is the optimal chemotherapy for oligodendroglioma patients? Our study using data from the national prospective cohort POLA found better PFS and OS outcomes with first-line RT/PCV compared to RT/TMZ ascopubs.org/doi/10.1200/JC…

Thrilled to introduce "The Epigenetic Hallmarks of Cancer", our Cancer Discovery Cancer Discovery AACR article. A team work by Mark Dawson Mark Dawson, Cigall Kadoch Cigall Kadoch, Feyruz Rassool, Peter Jones, Steve Baylin and yours truly. Enjoy! aacrjournals.org/cancerdiscover…

Happy to share our accepted manuscript, led by Franziska Ippen, on hemizygous CDKN2A/B deletions in IDH-mutant gliomas. Based on our manual assessment, we found no significant impact on survival in our cohort. academic.oup.com/neuro-oncology…

Great work!